Clearside Biomedical 배당금 및 환매

배당금 기준 확인 0/6

Clearside Biomedical 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-18.4%

환매 수익률

총 주주 수익률	-18.4%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 CLSD 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: CLSD 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Clearside Biomedical 시장 대비 배당 수익률

CLSD 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (CLSD)	n/a
시장 하위 25% (US)	1.3%
시장 상위 25% (US)	4.2%
업계 평균 (Pharmaceuticals)	2.4%
애널리스트 예측 (CLSD) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CLSD 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CLSD 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CLSD 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: CLSD 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Clearside Biomedical 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

High number of new directors

Clearside Biomedical: A Pivotal 2022 Ahead

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Price target decreased to US$10.40

Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.052 loss in 3Q 2020)

Independent Director exercised options to buy US$215k worth of stock.

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus revenue estimates increase to US$24.9m